The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Financial support is being provided as a grant from the Government of India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
